At a glance
ClinicalIndex Comparison RecordN/ACompleted· 76 enrolled
Drug / intervention
AcrySof® IQ PanOptix™ IOLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Investigation of the AcrySof® IQ PanOptix™ IOL Model TFNT00
In Brief
A clinical study evaluating AcrySof® IQ PanOptix™ IOL for Cataract. Completed, enrolled 76 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of the AcrySof® IQ PanOptix™ Intraocular Lens (IOL) Model TFNT00 when implanted to replace the natural lens following cataract removal.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartApr 2017
Primary CompletionFeb 2018
TodayJul 2026
First PostedMar 24, 2017
Enrollment StartApr 11, 2017
Primary CompletionFeb 13, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.3 years ago
Interventions
AcrySof® IQ PanOptix™ IOLdevice
Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient